{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:31:59Z","timestamp":1793428319663,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"31","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T cell exhaustion plays critical roles in tumor immune evasion. Novel strategies to suppress immune evasion are in urgent need. We aimed to identify potential compounds to target T cell exhaustion and increase response to immune checkpoint inhibitors (ICIs). Differentially expressed genes (DEGs) were identified between tumors with different immune evasion potential by comparing the transcriptome data. DEGs were then analyzed in the Connectivity Map (CMap) platform to identify potential compounds to increase response to ICIs. Gene set enrichment analysis, LDH release assay, Chromatin immunoprecipitation (ChIP), and Co-IP were performed to explore the potential mechanisms in vitro. Patients derived organoids and humanized xenograft mouse model were utilized to validate the finding ex vivo and in vivo. We identified 25 potential compounds that may play critical roles in regulating tumor immune evasion. We further pinpointed a specific compound, dexamethasone, which shows potent anti-tumor effect in multiple cancer cell lines when cocultured with T cells. Dexamethasone can suppress T cell exhaustion by decreasing the activity of two immune checkpoints simultaneously, including PD-L1 and IDO1. Functional study shows dexamethasone can increase the sensitivity of ICIs in coculture system, 3D organoid model and humanized mouse model. Mechanism study shows dexamethasone mediated transcriptional suppression of PD-L1 and IDO1 depends on the nuclear translocation of GR\/STAT3 complex. These findings demonstrate dexamethasone can suppress immune evasion by inducing GR\/STAT3 mediated downregulation of PD-L1 and IDO1 pathways.<\/jats:p>","DOI":"10.1038\/s41388-021-01897-0","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T13:02:37Z","timestamp":1624712557000},"page":"5002-5012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Dexamethasone suppresses immune evasion by inducing GR\/STAT3 mediated downregulation of PD-L1 and IDO1 pathways"],"prefix":"10.1038","volume":"40","author":[{"given":"Zhen","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-2223","authenticated-orcid":false,"given":"Zhijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranlin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-5364","authenticated-orcid":false,"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-9130","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-3252","authenticated-orcid":false,"given":"Yingyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"1897_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44:1255\u201369.","journal-title":"Immunity"},{"key":"1897_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/cells2020202","volume":"2","author":"AL Gruver-Yates","year":"2013","unstructured":"Gruver-Yates AL, Cidlowski JA. Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword. Cells. 2013;2:202\u201323.","journal-title":"Cells"},{"key":"1897_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/eji.201242613","volume":"43","author":"I Harpaz","year":"2013","unstructured":"Harpaz I, Abutbul S, Nemirovsky A, Gal R, Cohen H, Monsonego A. Chronic exposure to stress predisposes to higher autoimmune susceptibility in C57BL\/6 mice: glucocorticoids as a double-edged sword. Eur J Immunol. 2013;43:758\u201369.","journal-title":"Eur J Immunol"},{"key":"1897_CR4","first-page":"1181","volume":"15","author":"DL Conn","year":"1988","unstructured":"Conn DL, Tompkins RB, Nichols WL. Glucocorticoids in the management of vasculitis-a double edged sword? J Rheumatol. 1988;15:1181\u20133.","journal-title":"J Rheumatol"},{"key":"1897_CR5","doi-asserted-by":"crossref","unstructured":"Smolen JS. Response to: \u2018Correspondence on \u2018Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study\u201d by Charles. Ann Rheum Dis. 2021.","DOI":"10.1136\/annrheumdis-2021-220164"},{"key":"1897_CR6","doi-asserted-by":"crossref","unstructured":"AlBahrani S, Al-Tawfiq JA, Alshaer AR, Shilash A, Alswefy K, Al-Zayer RS et al. A case series of severe hospitalized COVID-19 patients treated with Tocilizumab and glucocorticoids: a report from Saudi Arabian hospital. J Epidemiol Glob Health. 2021.","DOI":"10.2991\/jegh.k.210112.001"},{"key":"1897_CR7","first-page":"1","volume":"18","author":"TC Hsieh","year":"2021","unstructured":"Hsieh TC, Sostin O. Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids. Ann Hematol. 2021;18:1\u20132.","journal-title":"Ann Hematol"},{"key":"1897_CR8","doi-asserted-by":"crossref","unstructured":"De Santis M, Voza A, Savevski V, Badalamenti S, Cecconi M, Mantovani A et al. Correspondence on \u2018Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study\u2019. Ann Rheum Dis. 2021.","DOI":"10.1136\/annrheumdis-2021-220044"},{"key":"1897_CR9","doi-asserted-by":"crossref","unstructured":"Ramiro S, Mostard RLM, Landewe RBM Response to: \u2018Correspondence on \u2018Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study\u201d by De Santis et al. Ann Rheum Dis. 2021.","DOI":"10.1136\/annrheumdis-2021-220077"},{"key":"1897_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56\u201361.","journal-title":"Science"},{"key":"1897_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","volume":"176","author":"J Wang","year":"2018","unstructured":"Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2018;176:334\u201347.","journal-title":"Cell"},{"key":"1897_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"1897_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400\u201316 e411.","journal-title":"Cell"},{"key":"1897_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437\u201352 e1417.","journal-title":"Cell"},{"key":"1897_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2020-218479","volume":"79","author":"S Ramiro","year":"2020","unstructured":"Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79:1143\u201351.","journal-title":"Ann Rheum Dis"},{"key":"1897_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.12788\/jhm.3497","volume":"15","author":"MJ Keller","year":"2020","unstructured":"Keller MJ, Kitsis EA, Arora S, Chen JT, Agarwal S, Ross MJ, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med. 2020;15:489\u201393.","journal-title":"J Hosp Med"},{"key":"1897_CR18","doi-asserted-by":"crossref","unstructured":"Charles P Correspondence on \u2018Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study\u2019. Ann Rheum Dis. 2021.","DOI":"10.1136\/annrheumdis-2021-219986"},{"key":"1897_CR19","doi-asserted-by":"crossref","unstructured":"Ramiro S, Mostard RLM, Landewe RBM Response to: \u2018Correspondence on \u2018Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study\u201d by Charles. Ann Rheum Dis. 2021.","DOI":"10.1136\/annrheumdis-2021-220001"},{"key":"1897_CR20","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/onc.2017.108","volume":"36","author":"Z Xiang","year":"2017","unstructured":"Xiang Z, Zhou ZJ, Xia GK, Zhang XH, Wei ZW, Zhu JT, et al. A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. Oncogene. 2017;36:5122\u201333.","journal-title":"Oncogene"},{"key":"1897_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3389\/fphar.2018.00861","volume":"9","author":"Z Xiang","year":"2018","unstructured":"Xiang Z, Huang X, Wang J, Zhang J, Ji J, Yan R, et al. Cross-database analysis reveals sensitive biomarkers for combined therapy for ERBB2+ gastric cancer. Front Pharm. 2018;9:861.","journal-title":"Front Pharm"},{"key":"1897_CR22","doi-asserted-by":"publisher","first-page":"13655","DOI":"10.1073\/pnas.1714587115","volume":"114","author":"Y Langut","year":"2017","unstructured":"Langut Y, Talhami A, Mamidi S, Shir A, Zigler M, Joubran S, et al. PSMA-targeted polyinosine\/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice. Proc Natl Acad Sci USA. 2017;114:13655\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1897_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11684-019-0679-7","volume":"13","author":"Z Xiang","year":"2019","unstructured":"Xiang Z, Yu Y. Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases. Front Med. 2019;13:24\u201331.","journal-title":"Front Med"},{"key":"1897_CR24","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"1897_CR25","doi-asserted-by":"crossref","unstructured":"Epacadostat Shows Value in Two SCCHN Trials. Cancer Discov. 2017;7:OF2.","DOI":"10.1158\/2159-8290.CD-NB2017-100"},{"key":"1897_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","volume":"41","author":"AJ Muller","year":"2018","unstructured":"Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin Immunopathol.2018;41:41\u20138.","journal-title":"Semin Immunopathol."},{"key":"1897_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fonc.2018.00423","volume":"8","author":"T Komiya","year":"2018","unstructured":"Komiya T, Huang CH. Updates in the clinical development of epacadostat and other Indoleamine 2,3-dioxygenase 1 inhibitors (IDO1) for human cancers. Front Oncol. 2018;8:423.","journal-title":"Front Oncol"},{"key":"1897_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.drudis.2017.10.009","volume":"23","author":"B Delavan","year":"2018","unstructured":"Delavan B, Roberts R, Huang R, Bao W, Tong W, Liu Z. Computational drug repositioning for rare diseases in the era of precision medicine. Drug Disco Today. 2018;23:382\u201394.","journal-title":"Drug Disco Today"},{"key":"1897_CR29","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1080\/15384101.2015.1033591","volume":"14","author":"G Manzotti","year":"2015","unstructured":"Manzotti G, Parenti S, Ferrari-Amorotti G, Soliera AR, Cattelani S, Montanari M, et al. Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules identified through interrogation of the Connectivity Map database. Cell Cycle. 2015;14:2578\u201389.","journal-title":"Cell Cycle"},{"key":"1897_CR30","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36:2872\u20138.","journal-title":"J Clin Oncol"},{"key":"1897_CR31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.eururo.2014.10.004","volume":"67","author":"R Venkitaraman","year":"2015","unstructured":"Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol. 2015;67:673\u20139.","journal-title":"Eur Urol"},{"key":"1897_CR32","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.4161\/cbt.7.7.6099","volume":"7","author":"JH Egberts","year":"2008","unstructured":"Egberts JH, Schniewind B, Patzold M, Kettler B, Tepel J, Kalthoff H, et al. Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol Ther. 2008;7:1044\u201350.","journal-title":"Cancer Biol Ther"},{"key":"1897_CR33","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-17-0807","volume":"23","author":"C Calagua","year":"2017","unstructured":"Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, et al. Expression of PD-L1 in hormone-naive and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide. Clin Cancer Res. 2017;23:6812\u201322.","journal-title":"Clin Cancer Res"},{"key":"1897_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/glia.22734","volume":"63","author":"M Ott","year":"2015","unstructured":"Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, et al. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia. 2015;63:78\u201390.","journal-title":"Glia"},{"key":"1897_CR35","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","volume":"130","author":"A Badros","year":"2017","unstructured":"Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma. Blood. 2017;130:1189\u201397.","journal-title":"Blood"},{"key":"1897_CR36","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2021.01.024","volume":"147","author":"E Pontali","year":"2021","unstructured":"Pontali E, Volpi S, Signori A, Antonucci G, Castellaneta M, Buzzi D, et al. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. J Allergy Clin Immunol. 2021;147:1217\u201325.","journal-title":"J Allergy Clin Immunol"},{"key":"1897_CR37","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2665-9913(21)00005-9","volume":"3","author":"PC Robinson","year":"2021","unstructured":"Robinson PC, Morand E. Divergent effects of acute versus chronic glucocorticoids in COVID-19. Lancet Rheumatol. 2021;3:e168\u201370.","journal-title":"Lancet Rheumatol"},{"key":"1897_CR38","first-page":"2854186","volume":"2020","author":"HY Fu","year":"2020","unstructured":"Fu HY, Luo Y, Gao JP, Wang L, Li HJ, Li X, et al. Effects of short-term low-dose glucocorticoids for patients with mild COVID-19. Biomed Res Int. 2020;2020:2854186.","journal-title":"Biomed Res Int"},{"key":"1897_CR39","doi-asserted-by":"publisher","first-page":"108441","DOI":"10.1016\/j.diabres.2020.108441","volume":"168","author":"G Li","year":"2020","unstructured":"Li G. Inpatient use of glucocorticoids may mediate the detrimental effect of new-onset hyperglycemia on COVID-19 severity. Diabetes Res Clin Pr. 2020;168:108441.","journal-title":"Diabetes Res Clin Pr"},{"key":"1897_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14572","volume":"8","author":"J Lau","year":"2017","unstructured":"Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572.","journal-title":"Nat Commun"},{"key":"1897_CR41","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.7150\/ijbs.58695","volume":"17","author":"R Yang","year":"2021","unstructured":"Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. Int J Biol Sci. 2021;17:1530\u20137.","journal-title":"Int J Biol Sci"},{"key":"1897_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48:434\u201352.","journal-title":"Immunity"},{"key":"1897_CR43","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ptr.5327","volume":"29","author":"N Arumuggam","year":"2015","unstructured":"Arumuggam N, Bhowmick NA, Rupasinghe HP. A review: phytochemicals targeting JAK\/STAT signaling and IDO expression in cancer. Phytother Res. 2015;29:805\u201317.","journal-title":"Phytother Res"},{"key":"1897_CR44","doi-asserted-by":"publisher","first-page":"e19823","DOI":"10.1371\/journal.pone.0019823","volume":"6","author":"CA Opitz","year":"2011","unstructured":"Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, et al. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One. 2011;6:e19823.","journal-title":"PLoS One"},{"key":"1897_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436\u201344.","journal-title":"Nature"},{"key":"1897_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nrm1834","volume":"7","author":"M Gaestel","year":"2006","unstructured":"Gaestel M. MAPKAP kinases - MKs - two\u2019s company, three\u2019s a crowd. Nat Rev Mol Cell Biol. 2006;7:120\u201330.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1897_CR47","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.4049\/jimmunol.0804388","volume":"182","author":"Y Sun","year":"2009","unstructured":"Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T, et al. Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol. 2009;182:5899\u2013903.","journal-title":"J Immunol"},{"key":"1897_CR48","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008;105:20852\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1897_CR49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.molcel.2012.04.021","volume":"47","author":"D Langlais","year":"2012","unstructured":"Langlais D, Couture C, Balsalobre A, Drouin J. The Stat3\/GR interaction code: predictive value of direct\/indirect DNA recruitment for transcription outcome. Mol Cell. 2012;47:38\u201349.","journal-title":"Mol Cell"},{"key":"1897_CR50","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.cell.2018.07.027","volume":"174","author":"K Nanki","year":"2018","unstructured":"Nanki K, Toshimitsu K, Takano A, Fujii M, Shimokawa M, Ohta Y, et al. Divergent routes toward wnt and r-spondin niche independency during human gastric carcinogenesis. Cell. 2018;174:856\u201369 e817.","journal-title":"Cell"},{"key":"1897_CR51","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175:1972\u201388 e1916.","journal-title":"Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01897-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T05:04:36Z","timestamp":1628139876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01897-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":51,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2021,8,5]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-01897-0","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"COMPETING INTERESTS"}},{"value":"This study was approved by the Research Ethics Committee of Shanghai Jiaotong University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consents were obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}